

Resource Summary Report

Generated by [NIF](#) on Sep 15, 2026

APC/Fire(TM) 750 anti-mouse CD4

RRID:AB_2715955

Type: Antibody

Proper Citation

BioLegend Cat# 116019, RRID:AB_2715955

Antibody Information

URL: http://antibodyregistry.org/AB_2715955

Proper Citation: BioLegend Cat# 116019, RRID:AB_2715955

Target Antigen: CD4

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC/Fire(TM) 750 anti-mouse CD4

Description: This monoclonal targets CD4

Target Organism: mouse

Clone ID: Clone RM4-4

Antibody ID: AB_2715955

Vendor: BioLegend

Catalog Number: 116019

Alternative Catalog Numbers: 116020

Record Creation Time: 20231110T033808+0000

Record Last Update: 20260829T083054+0000

Ratings and Alerts

No rating or validation information has been found for APC/Fire(TM) 750 anti-mouse CD4.

No alerts have been found for APC/Fire(TM) 750 anti-mouse CD4.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Triana-Martinez F, et al. (2026) p16High immune cells control disease tolerance as a defense and health span-extending strategy. *Immunity*, 59(6), 1633.

Mout R, et al. (2025) Design of soluble Notch agonists that drive T cell development and boost immunity. *Cell*.

Lubrano S, et al. (2025) FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma. *Cancer cell*, 43(3), 428.

van der Heide V, et al. (2025) Prolonged but finite antigen presentation promotes reversible defects of "helpless" memory CD8+ T cells. *Immunity*, 58(7), 1742.

Lin F, et al. (2024) Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. *Cell*, 187(26), 7470.

Arang N, et al. (2023) High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma. *Cell reports. Medicine*, 4(11), 101244.

Miyai Y, et al. (2022) Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade. *Life science alliance*, 5(6).